Published in Cancer Res on December 01, 1976
The glucocorticoid receptor: a revisited target for toxins. Toxins (Basel) (2010) 0.81
Quantitative electron microscopy of carcinogen-induced alterations in hepatocyte rough endoplasmic reticulum. II. Modulation of the effects of 3'MeDAB by adrenalectomy and adrenal corticosteroids. Br J Exp Pathol (1989) 0.75
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A (2001) 6.78
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res (1993) 6.31
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev (1994) 4.62
Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet (1992) 4.11
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA (1994) 4.01
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol (1993) 3.56
Chemical nature and biological effects of the aflatoxins. Bacteriol Rev (1966) 3.44
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res (1994) 3.18
Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci U S A (1994) 2.73
Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc Natl Acad Sci U S A (1977) 2.53
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res (2001) 2.50
Aflatoxin B1: binding to DNA in vitro and alteration of RNA metabolism in vivo. Science (1966) 2.46
American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol (1999) 2.35
Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol (1999) 2.22
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res (2000) 2.18
Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet (2001) 2.16
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst (1990) 2.15
Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol Med (2001) 2.10
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res (1991) 2.08
Characterization of c-Ki-ras oncogene alleles by direct sequencing of enzymatically amplified DNA from carcinogen-induced tumors. Proc Natl Acad Sci U S A (1987) 1.98
Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst (1999) 1.92
Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem (1994) 1.91
Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res (1998) 1.91
Dose-response characteristics of aflatoxin B1 carcinogenesis in the rat. Cancer Res (1967) 1.82
Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res (1995) 1.82
Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proc Natl Acad Sci U S A (2009) 1.81
Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res (1996) 1.77
The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia (1998) 1.75
Human cell mutagenicity of oxygenated, nitrated and unsubstituted polycyclic aromatic hydrocarbons associated with urban aerosols. Mutat Res (1996) 1.74
In vitro reactions of aflatoxin B1-adducted DNA. Proc Natl Acad Sci U S A (1981) 1.73
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res (2000) 1.70
Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res (1996) 1.69
DNA methylation in breast cancer. Endocr Relat Cancer (2001) 1.68
Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver. Proc Natl Acad Sci U S A (1978) 1.64
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol (1988) 1.59
Temporal patterns of covalent DNA adducts in rat liver after single and multiple doses of aflatoxin B1. Cancer Res (1981) 1.59
The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res (1996) 1.56
Oxidative mechanisms in carcinogenesis. Br Med Bull (1993) 1.54
Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci U S A (2001) 1.54
Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res (2001) 1.51
Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol (1994) 1.50
Nitric oxide-induced mutations in the HPRT gene of human lymphoblastoid TK6 cells and in Salmonella typhimurium. Environ Mol Mutagen (2000) 1.46
An overview of the relationship between oxidative stress and chemical carcinogenesis. Free Radic Biol Med (1991) 1.44
Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci U S A (2000) 1.44
Improved procedure for production of cytochalasin E and tremorgenic mycotoxins by Aspergillus clavatus. Appl Environ Microbiol (1976) 1.42
The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A (1991) 1.40
Role of reactive oxygen species in modulation of Nrf2 following ischemic reperfusion injury. Neuroscience (2007) 1.39
Sequential morphologic changes in aflatoxin B carcinogenesis in the rat. Cancer Res (1968) 1.33
Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem (1997) 1.32
Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene (2008) 1.31
Mycotoxins. Annu Rev Pharmacol (1975) 1.29
Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res (1987) 1.27
Antioxidant-inducible genes. Adv Pharmacol (1997) 1.24
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res (1992) 1.23
Association between aflatoxin content of food and hepatoma frequency in Uganda. Cancer (1971) 1.23
Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1. Carcinogenesis (1988) 1.23
High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst (1991) 1.23
Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia (2001) 1.23
Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res (2001) 1.22
NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park) (2000) 1.22
Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev (1993) 1.21
Peroxynitrite-induced mutation spectra of pSP189 following replication in bacteria and in human cells. Mutat Res (1996) 1.21
Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2001) 1.20
Myeloperoxidase as a biomarker of skin irritation and inflammation. Food Chem Toxicol (1994) 1.19
Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res (1994) 1.19
Chemical and biochemical dosimetry of exposure to genotoxic chemicals. Environ Health Perspect (1985) 1.18
Induction of hepatic heme oxygenase-1 and ferritin in rats by cancer chemopreventive dithiolethiones. Carcinogenesis (1996) 1.18
Nuclear distribution of aflatoxin B1 and its interaction with histones in rat liver in vivo. Cancer Res (1980) 1.18
Excretion of an aflatoxin-guanine adduct in the urine of aflatoxin B1-treated rats. Cancer Res (1981) 1.17
Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc Natl Acad Sci U S A (1985) 1.17
Aflatoxin exposure in human populations: measurements and relationship to cancer. Crit Rev Toxicol (1988) 1.16
Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res (1991) 1.15
Antioxidative function and substrate specificity of NAD(P)H-dependent alkenal/one oxidoreductase. A new role for leukotriene B4 12-hydroxydehydrogenase/15-oxoprostaglandin 13-reductase. J Biol Chem (2001) 1.15
Time course of alterations of rat liver polysome profiles induced by aflatoxin B 1 . Biochem Pharmacol (1969) 1.14
Monoclonal antibody to aflatoxin B1-modified DNA detected by enzyme immunoassay. Proc Natl Acad Sci U S A (1981) 1.14
Identification of an activated c-Ki-ras oncogene in rat liver tumors induced by aflatoxin B1. Proc Natl Acad Sci U S A (1986) 1.13
Chemical and toxicological characterization of residential oil burner emissions: II. Mutagenic, tumorigenic, and potential teratogenic activity. Environ Health Perspect (1987) 1.13
Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res (1995) 1.13
Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Cancer Epidemiol Biomarkers Prev (1996) 1.12
Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res (1986) 1.11
Molecular dosimetry of aflatoxin-N7-guanine in human urine obtained in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev (1993) 1.09
Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis (1994) 1.09
Inhibition of tumor promotion by a biomimetic superoxide dismutase. Science (1983) 1.09
Letter: structure of cytochalasin E, a toxic metabolite of Aspergillus clavatus. J Am Chem Soc (1973) 1.09
Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev (1997) 1.09
Structure-activity relationships in toxicity and carcinogenicity of aflatoxins and analogs. Cancer Res (1971) 1.09
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst (1995) 1.08
Tumorigenicity of fluoranthene in a newborn mouse lung adenoma bioassay. Carcinogenesis (1984) 1.08
Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. J Biol Chem (1999) 1.08